flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019.

Collaborations | 23 August 19
Read more
23
Aug
2019

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019.

20
Aug
2019

Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME

• Combination therapy did not show increase in BCVA in the overall population at Month 3.
• Certain improvement in mean BCVA at Month 3 observed with the combination therapy in 2 pre-specified subgroups:
Poor (or non) responders to prior anti-VEGF and patients with poor vision - baseline BCVA ≤65 letters
• Topline data confirm THR-317 in combination with ranibizumab is safe and well-tolerated

20
Aug
2019

Mithra Signs LSA for Commercialization of Estelle® and Myring™ in Israel

  • Mithra grants exclusive license to Dexcel Pharma for commercialization of its two leading contraceptive products in Israel
  • Dexcel Pharma is Israel’s largest private pharmaceutical company
  • Production at the Mithra CDMO facility in Belgium
20
Aug
2019

Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months

• Yorkville continues to support Genkyotex and its development plans
• The Company has purchased back from remaining existing convertible notes of €1.6 million and issued new convertible notes for equivalent

20
Aug
2019

MyCartis to spin out point-of-need diagnostics business in new company ANTELOPE Dx.

An investment consortium, with RMM (Rudi Marien) and Saffelberg (Jos Sluys) as lead investors, has invested in the new spin-off Antelope Dx. Together with some high net worth individuals, they have invested 5,1 million EUR in the new diagnostic company that develops innovative technology and applications for point-of-care testing.

23
Aug
2019

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019.

20
Aug
2019

Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME

• Combination therapy did not show increase in BCVA in the overall population at Month 3.
• Certain improvement in mean BCVA at Month 3 observed with the combination therapy in 2 pre-specified subgroups:
Poor (or non) responders to prior anti-VEGF and patients with poor vision - baseline BCVA ≤65 letters
• Topline data confirm THR-317 in combination with ranibizumab is safe and well-tolerated

20
Aug
2019

Mithra Signs LSA for Commercialization of Estelle® and Myring™ in Israel

  • Mithra grants exclusive license to Dexcel Pharma for commercialization of its two leading contraceptive products in Israel
  • Dexcel Pharma is Israel’s largest private pharmaceutical company
  • Production at the Mithra CDMO facility in Belgium
20
Aug
2019

Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months

• Yorkville continues to support Genkyotex and its development plans
• The Company has purchased back from remaining existing convertible notes of €1.6 million and issued new convertible notes for equivalent

20
Aug
2019

MyCartis to spin out point-of-need diagnostics business in new company ANTELOPE Dx.

An investment consortium, with RMM (Rudi Marien) and Saffelberg (Jos Sluys) as lead investors, has invested in the new spin-off Antelope Dx. Together with some high net worth individuals, they have invested 5,1 million EUR in the new diagnostic company that develops innovative technology and applications for point-of-care testing.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?